Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-64565111 in Healthy Japanese and Caucasian Males
NCT03618160Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2018
- Primary completion
- Jun 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efinopegdutide in obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events, Maximum Observed Serum Concentration and 5 more. Started Aug 2018; status: terminated.
02
Drugs
efinopegdutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03618160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618160.